Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 16/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.64 |
| ▸ | CCR2 | P41597 | 1/20 | 0.64 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6854898 | 0.97 | CXCR4 (0.61) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL673242 | 0.80 | CXCR4 (0.61) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL5611617 | 0.78 | CXCR4 (1.00) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL29490414 | 0.78 | CXCR4 (1.00) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Plerixafor SCHEMBL19038 | 0.78 | CXCR4 (1.00) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Bromide SCHEMBL1257497 | 0.77 | CXCR4 (0.58) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Plerixafor SCHEMBL414153 | 0.76 | CXCR4 (1.00) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Hydrochloric Acid SCHEMBL7612104 | 0.76 | CXCR4 (1.00) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Hydrochloric Acid SCHEMBL7610931 | 0.76 | CXCR4 (1.00) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Plerixafor SCHEMBL6889125 | 0.76 | CXCR4 (1.00) | CXCR4MEN1CHRM2CHRM1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935692-B2 | Methods to mobilize progenitor/stem cells | GENZYME CORPORATION (US) | 2011-05-03 | — | — | US | claimed |
| US-RE42152-E1 | Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity | GENZYME CORPORATION (US) | 2011-02-15 | — | — | US | claimed |
| EP-0619813-B1 | LINKED CYCLIC POLYAMINES WITH ACTIVITY AGAINST HIV | ANORMED INC (CA) | 2004-08-18 | — | — | EP | claimed |
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | KEEFER, Edward (US) | 2024-08-29 | — | — | US | disclosed |
| CN-111712262-A | Dosing regimens for mobilizing hematopoietic stem and progenitor cells | 美真达治疗公司 | 2020-09-25 | — | — | CN | disclosed |
| US-20150030561-A1 | Use of CXCR4 Antagonists | GENZYME CORP. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20110245265-A1 | CXCR4 ANTAGONISTS FOR KIDNEY INJURY | GENZYME CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| US-20100178271-A1 | Combination Therapy | GENZYME CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100003224-A1 | Combination Therapy | GENZYME CORPORATION (US) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245265-A1 | CXCR4 ANTAGONISTS FOR KIDNEY INJURY | CXCR4, CXCR3, CXCR1 | CXCR4 1/4885MEN1 4650/4885CHRM2 1505/4885 |
| US-20150030561-A1 | Use of CXCR4 Antagonists | CXCR4, CXCR2, CXCR3 | CXCR4 1/4885MEN1 3707/4885CHRM2 1420/4885 |
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | CXCR3, CXCL12, CXCR4 | CXCR4 3/4885MEN1 4348/4885CHRM2 847/4885 |
| US-20100178271-A1 | Combination Therapy | CXCL12, CSF3R, CXCR4 | CXCR4 3/4885MEN1 1508/4885CHRM2 3149/4885 |
| US-20100003224-A1 | Combination Therapy | CXCL12, CXCR4, SDF4 | CXCR4 2/4885MEN1 679/4885CHRM2 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.